Figure_5.tif (1.76 MB)

Org 214007-0 is equally effective as prednisolone in acute inflammation mouse models.

figure

posted on 2012-11-12, 02:20 authored by Marie-José C. van Lierop, Wynand Alkema, Anke J. Laskewitz, Rein Dijkema, Hans M. van der Maaden, Martin J. Smit, Ralf Plate, Paolo G. M. Conti, Christan G. J. M. Jans, C. Marco Timmers, Constant A. A. van Boeckel, Scott J. Lusher, Ross McGuire, Rene C. van Schaik, Jacob de Vlieg, Ruben L. Smeets, Claudia L. Hofstra, Annemieke M. H. Boots, Marcel van Duin, Benno A. Ingelse, Willem G. E. J. Schoonen, Aldo Grefhorst, Theo H. van Dijk, Folkert Kuipers, Wim H. A. Dokter

A) Inhibition of acute inflammation in the LPS-induced TNFα mouse model. Mean percentage inhibition (of each group of n = 8) (± SEM) of the LPS-induced TNFα release by the vehicle treated group is shown (no TNFα is detectable without LPS injection). ** = significantly different from placebo (p<0.01; ANOVA-test). B) Inhibition of acute T cell-driven inflammation in the anti-CD3-induced IL-2 mouse model. Org 214007-0 shows a more potent activity than prednisolone in this model. Mean percentage inhibition (of each group of n = 2) (± SEM) of the anti-CD3-induced IL-2 release relative to a positive control group (treated with 10 mg/kg A420983, a pan-SRC inhibitor) (set at 100%) is shown (no IL-2 is detectable without anti-CD3 injection). ** = significantly different from placebo (p<0.01; ANOVA-test).